Solid Tumor — Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Citation(s)
A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer